EGFR and skin neoplasm: Clinicians use NGS to identify actionable mutations (such as epidermal growth factor receptor (EGFR) for pulmonary carcinoma, or BRAF in the case of skin cancer) and adapt the treatment for optimal efficacy [1–7].